Green day on Friday for Catalyst Pharmaceuticals
(Updated on Sep 30, 2022)
Sell candidate since 2022-09-19 Loss -1.08% PDF
The Catalyst Pharmaceuticals stock price gained 1.02% on the last trading day (Friday, 30th Sep 2022), rising from $12.70 to $12.83. During the last trading day the stock fluctuated 4.84% from a day low at $12.60 to a day high of $13.21. The price has fallen in 6 of the last 10 days and is down by -4.33% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 338 thousand more shares were traded than the day before. In total, 2 million shares were bought and sold for approximately $28.04 million.
The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $12.40 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 66.04% during the next 3 months and, with a 90% probability hold a price between $20.59 and $27.88 at the end of this 3-month period.
Signals & Forecast
There are mixed signals in the stock today. The Catalyst Pharmaceuticals stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $13.75. On a fall, the stock will find some support from the short-term average at $12.41. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. A sell signal was issued from a pivot top point on Wednesday, September 14, 2022, and so far it has fallen -17.33%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal.
Support, Risk & Stop-loss
This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.61 between high and low, or 4.84%. For the last week, the stock has had daily average volatility of 3.84%.
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations For The Upcoming Trading Day Of Monday 3rd
For the upcoming trading day on Monday, 3rd we expect Catalyst Pharmaceuticals to open at $12.88, and during the day (based on 14 day Average True Range), to move between $12.09 and $13.57, which gives a possible trading interval of +/-$0.74 (+/-5.77%) up or down from last closing price. If Catalyst Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 11.54% move between the lowest and the highest trading price during the day.
Since the stock is closer to the support from accumulated volume at $12.75 (0.62%) than the resistance at $13.62 (6.16%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..
Is Catalyst Pharmaceuticals stock A Buy?
Catalyst Pharmaceuticals holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
Current score: -3.414Sell Candidate Unchanged
Predicted Opening Price for Catalyst Pharmaceuticals of Monday, October 3, 2022
The predicted opening price is based on yesterday's movements between high, low, and closing price.
|Fair opening price October 3, 2022||Current price|
Remember To Visit Our YouTube Channel
Fibonacci Support & Resistance Levels
Accumulated Volume Support & Resistance Levels
Click to get the best stock tips daily for free!
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develop... CPRX Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.